Skip to main content
AZTR
NYSE Life Sciences

Azitra Q3 10-Q: Going-Concern Doubt, $3.75M Cash, Equity Below NYSE American Minimum

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.722
Mkt Cap
$4.051M
52W Low
$0.518
52W High
$5.591
52W Position info
39% above low
Off High info
87% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

AZTR sits 39% above its 52-week low of $0.518 on light trading volume (0.1× avg).

Summary

Azitra posted a $2.95 million Q3 net loss with $3.75 million of cash and explicit going-concern doubt, while equity of about $4.4 million sits below the NYSE American minimum and 21.9 million warrants overhang 6.06 million shares.


Key Events · Earnings and Guidance · AZTR

  • Going-Concern Doubt Disclosed

    Management states substantial doubt about the ability to continue as a going concern for twelve months, citing a $78.7 million accumulated deficit, a $10.3 million operating loss and $8.7 million of cash used in operations for the nine months ended September 30, 2026.

  • Cash Position and Quarterly Loss

    Cash and cash equivalents stood at $3,750,710 at September 30, 2026, up from $2,068,083 at December 31, 2025 after a $10.4 million March private placement; the Q3 net loss was $2,949,779 versus $2,764,528 a year earlier.

  • Equity Below NYSE American Minimum

    Stockholders' equity of approximately $4.4 million at September 30, 2026 falls below the $6.0 million required by Section 1003(a)(iii); a repeat breach within 12 months of the August 19, 2026 compliance notice could let the exchange shorten or skip the cure period.

  • Warrant Overhang Dwarfs Share Count

    Warrants outstanding total 21,947,000 against 6,060,335 shares, including 16,884,612 Series B and Series C warrants at a $1.23 exercise price and 4,241,182 pre-funded warrants at $0.10; the Series C strike resets to the closing price if it is below $1.23 at termination.


Analysis · AZTR · Life Sciences

The headline is survival, not the quarter: Azitra closed September 30, 2026 with $3.75 million of cash and a $10.2 million nine-month operating loss, and management states plainly that substantial doubt exists about the company's ability to continue as a going concern for twelve months. The balance sheet is the immediate problem. Stockholders' equity of roughly $4.4 million sits below the $6.0 million minimum required by NYSE American Section 1003(a)(iii), only months after the company regained compliance on August 19, 2026 — and a repeat breach inside 12 months lets the exchange shorten or skip the cure process. The capital structure is the other half of the story: 21,947,000 warrants are outstanding against 6,060,335 shares, including 16,884,612 Series B/C warrants struck at $1.23, so any recovery in the share price converts into heavy dilution. Management also disclosed a material weakness in internal controls tied to inadequate segregation of accounting duties, and disclosure controls were concluded not effective. Financing options are narrowing too: the ATM was effectively abandoned on October 26, 2026 after raising just $126, leaving the $13.8 million remaining on the Alumni Capital equity line as the main financing valve.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AZTR was trading at $0.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.52 to $5.59. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AZTR - Latest Insights